How we choose featured affiliate partners

Two lists, two different jobs

We publish two ordered lists of GLP-1 telehealth providers, and we keep them clearly separate so readers can tell which is which:

1. The 2026 Provider Rankings (the full table on our homepage and at /) is methodology-sorted. Each provider receives a score computed from a five-axis rubric:
   • Cost & pricing transparency (25%)
   • Clinical support quality (25%)
   • Medication options (20%)
   • User experience (15%)
   • Insurance & accessibility (15%)

   The ranking is the order of those scores, descending. The full rubric and evidence behind each score live in our editorial policy and a public scoring registry in the repo.

   Affiliate status never affects the methodology score. That integrity firewall is enforced in the build itself: a script recomputes every score from evidence flags and fails the build if a verified provider drifts from its computed score.

2. Featured affiliate partners (the commercial cards on the homepage) are editorial and commercial, not methodology-sorted. Only providers that remain eligible under the current evidence can appear, so the number of placements is allowed to shrink.

A reader gets both: the curated shortlist for “just tell me what to look at first” intent, and the full methodology table for “show me the data so I can decide for myself” intent.

Every featured partner also appears in the full ranking at its score-earned position. A commercial placement never moves it up the objective methodology table.

How we curate featured placements

Every placement must clear all of these criteria. If new evidence makes a provider unsafe or misleading to promote, it leaves the list regardless of payout or conversion history.

• No disqualifying current evidence. An unresolved regulatory action, a corroborated systemic fulfillment pattern, or another material reader-risk finding can remove a provider immediately. Score and revenue cannot override that evidence.
• Active affiliate partner on the Katalys network. We're honest that this is a list optimized for active monetization. We label it as such and disclose it on every page.
• Price and product claims we can describe honestly. Introductory rates, plan commitments, medication-only figures, and unresolved totals must be labeled as such. A low headline never becomes an all-in promise merely because the provider is a partner.
• A defensible niche or differentiator. If a provider doesn't serve a distinguishable use case (cash-pay flat-rate, insurance-friendly, oral GLP-1, etc.), they're a duplicate of a stronger pick and don't earn the slot.
• Re-evaluated when evidence changes. Price drift, complaint patterns, regulatory actions, fulfillment failures, or product changes can remove a placement before any scheduled review. We do not add a weaker replacement just to restore a card count.

What earns a slot vs. what doesn't

What can affect commercial order: measured conversion performance and payout, but only among providers that already clear the evidence rules above.

That is the legitimate place for affiliate economics to play a role: ordering a plainly labeled commercial shortlist after editorial eligibility has been established.

What doesn't: a higher affiliate payout cannot rescue a provider with disqualifying evidence, and it never moves a provider up the methodology score. Two different lists, two different rules.

Current featured affiliate placements

• Embody (review)· Score 7.3 / 10 · from $69/mo · Affiliate partner
  People who want to compare Embody's published plan menu with its separate monthly promotion and will confirm the exact charge, term and refund rules before paying
• Gala (review)· Score 7.2 / 10 · from $149/mo · Affiliate partner
  Patients comparing Gala's $149/mo microdose on its 3-month promotional offer with the $179/mo yearly all-doses plan, and who will use its free companion app for progress logging
• Ro (review)· Score 7.2 / 10 · $149/mo membership + medication · Affiliate partner
  Users who want FDA-approved brand-name GLP-1 access including the new Foundayo (orforglipron) oral pill, with direct insurance billing
• Fridays (review)· Score 8.7 / 10 · from $117/mo · Affiliate partner
  Users who want a holistic program with coaching, nutrition support, and flexible pricing

Disclosures

We earn commissions on sign-ups to the providers above. Revenue can order eligible commercial placements, but it cannot change a score, an objective rank, or the evidence threshold for appearing here. Read the full affiliate disclosure and editorial policy for the integrity firewall in detail.